IDEXX Laboratories, Inc. $IDXX Shares Acquired by Focus Partners Wealth

Focus Partners Wealth boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,389 shares of the company’s stock after purchasing an additional 9,471 shares during the period. Focus Partners Wealth’s holdings in IDEXX Laboratories were worth $41,411,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Beacon Investment Advisory Services Inc. grew its holdings in IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after acquiring an additional 6,710 shares in the last quarter. Nordea Investment Management AB grew its holdings in IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares in the last quarter. NEOS Investment Management LLC grew its holdings in IDEXX Laboratories by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after acquiring an additional 13,599 shares in the last quarter. Procyon Advisors LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth $1,966,000. Finally, Diversified Trust Co. grew its holdings in IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after acquiring an additional 2,901 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on IDXX. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Trading Up 1.6%

IDEXX Laboratories stock opened at $570.00 on Tuesday. The firm’s 50-day moving average is $563.07 and its 200-day moving average is $625.43. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a market cap of $44.96 billion, a P/E ratio of 41.97, a PEG ratio of 3.07 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.